RCC stands for renal cell carcinoma, the most common type of kidney cancer in adults. It accounts for roughly 90% of all kidney cancers and originates in the lining of the tiny tubes inside the kidney that filter blood and produce urine. The median age at diagnosis is 65, and the overall five-year survival rate is 79%, though outcomes vary dramatically depending on how early it’s caught.
How RCC Is Usually Found
One of the most striking things about renal cell carcinoma is how quietly it develops. Up to 60% of cases are discovered by accident, when a person gets a CT scan or ultrasound for an entirely unrelated reason, like abdominal pain or a routine checkup. The tumor shows up as an unexpected mass on the kidney.
RCC does have a textbook set of warning signs: blood in the urine, flank pain, and a lump you can feel in the abdomen. But fewer than 10% of people have all three of those symptoms at the time of diagnosis. Many people have no symptoms at all until the cancer has grown significantly, which is why incidental detection through imaging has become so important. The increasing use of abdominal scans in modern medicine has actually shifted diagnosis earlier for many patients.
Subtypes of Renal Cell Carcinoma
Not all RCC behaves the same way. There are several subtypes based on how the cancer cells look under a microscope, and together, the three most common subtypes make up over 90% of cases:
- Clear cell RCC (75% of cases): The most common and most studied subtype. It’s named for the way the cells appear pale or “clear” when stained for examination. This subtype is strongly linked to a specific gene (VHL) that normally acts as a brake on tumor growth.
- Papillary RCC (10%): The second most common type, which tends to form finger-like projections of tissue. It can sometimes occur as multiple tumors in the same kidney.
- Chromophobe RCC (5%): Generally considered to have a better prognosis than clear cell, though it’s much less common.
The remaining cases include rarer subtypes. Knowing which subtype you have matters because it influences treatment decisions and expected outcomes.
Risk Factors
Several factors raise the likelihood of developing RCC, and some are modifiable.
Excess body weight is one of the biggest contributors. For every five-point increase in BMI, the risk of kidney cancer rises by about 24% in men and 34% in women. Researchers estimate that being overweight or obese accounts for up to 40% of kidney cancer cases in North America and 30% in Europe. That makes weight management one of the most impactful things a person can do to lower their risk.
Smoking is another established cause, though its effect is more moderate. Male smokers face about a 50% higher risk compared to nonsmokers, while female smokers have roughly a 20% increase. Heavy smokers (21 or more cigarettes a day) can double their risk. The good news: quitting brings the risk back down by 15% to 30% within 10 to 15 years. Overall, cigarette smoking is thought to account for 20% to 30% of kidney cancers in men and 10% to 20% in women.
Genetics also play a role. Several inherited conditions predispose people to RCC, the best known being von Hippel-Lindau disease, which specifically increases the risk of clear cell RCC. But even in people without an inherited syndrome, the majority of clear cell tumors involve inactivation of the same VHL gene through mutations that occur over a lifetime rather than being passed down from parents.
Staging and What It Means
Staging describes how far the cancer has spread, and it’s the single biggest factor in predicting outcomes. For RCC, tumor size is a key measurement. Tumors 4 centimeters or smaller are classified as T1a, those between 4 and 7 centimeters are T1b, and those larger than 7 centimeters but still confined to the kidney are T2. Beyond size, staging also considers whether the cancer has reached nearby lymph nodes or spread to distant organs.
The survival numbers paint a clear picture of why early detection matters so much. According to data from the American Cancer Society based on diagnoses between 2015 and 2021:
- Localized (still within the kidney): 93% five-year survival
- Regional (spread to nearby structures or lymph nodes): 76% five-year survival
- Distant (spread to other organs): 19% five-year survival
The gap between localized and distant disease is enormous, which is why those incidental findings on imaging scans can be genuinely life-saving.
How RCC Is Treated
Surgery is the primary treatment for RCC that hasn’t spread beyond the kidney. For smaller tumors (T1, up to 7 centimeters), European guidelines recommend removing only the tumor and a margin of healthy tissue while preserving the rest of the kidney. This approach, called partial nephrectomy, protects long-term kidney function. For larger tumors or those in difficult locations, removing the entire kidney may be necessary.
When cancer has spread to other parts of the body, treatment shifts to systemic therapy. The standard of care for metastatic RCC now combines two types of drugs: one that helps the immune system recognize and attack cancer cells, and another that cuts off the blood supply tumors need to grow. The FDA has approved several of these combination regimens since 2019, and they’ve consistently outperformed older single-drug approaches in clinical trials. These treatments don’t cure metastatic disease in most cases, but they can significantly extend survival and shrink tumors.
For very small tumors, particularly in older patients or those with other health conditions, doctors sometimes recommend active surveillance, meaning close monitoring with regular imaging rather than immediate surgery. This avoids the risks of an operation when the tumor may grow slowly or not at all.
Living After Diagnosis
For people whose RCC is caught at a localized stage, which is the majority of cases thanks to widespread imaging, the outlook is strongly favorable. After surgery, follow-up typically involves periodic imaging scans and blood work to check for recurrence. If only part of the kidney was removed, most people retain normal kidney function and don’t need any special dietary changes.
People who’ve had an entire kidney removed can live fully with one kidney, though protecting remaining kidney function becomes a priority. That means managing blood pressure, staying hydrated, and avoiding medications that are hard on the kidneys when possible. Recurrence can happen years after initial treatment, so long-term follow-up is standard, often extending to 10 years or more.